Perrigo to trial Ivermectin cream vs. Soolantra

A clinical trial has been listed that will compare an Ivermectin based cream made by Perrigo Company to a `reference’ Ivermectin product.

The reference product described as a “FDA approved product to treat the inflammatory lesions of rosacea” so will be Soolantra.

Perrigo might not be a well known brand – it promotes itself as;

Perrigo Company plc is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API) …
The company is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies.
Even if Perrigo can prove that they have an ivermectin based product that is comparable to Soolantra in treating rosacea, it is hard to see how they would be able to market it as a treatment for rosacea.

A competitor to Soolantra – that would be great news.

One topical ivermectin cream that is already available is Sklice, a prescription ivermectin 0.5% lotion for the treatment of head lice.

Clinical Trial NCT02795117

Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea

The purpose of this study is to compare the safety and efficacy of Perrigo’s product to an FDA approved product for the treatment of inflammatory lesions rosacea

Sponsor: Perrigo Company
Primary Outcome Measures: Mean percent change from baseline in the inflammatory (papules and pustules) lesion count [ Time Frame: Day 84 ]
Experimental: Test product
Active Comparator: Reference product
Placebo Comparator: Placebo product

 Related Articles

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed Connect on Pinterest Connect on Google Plus

Leave a Comment

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.